<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page2_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page2_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>McDowall</o:LastAuthor>
  <o:Revision>29</o:Revision>
  <o:TotalTime>815</o:TotalTime>
  <o:Created>2004-11-17T15:22:00Z</o:Created>
  <o:LastSaved>2004-12-06T18:37:00Z</o:LastSaved>
  <o:Pages>3</o:Pages>
  <o:Words>1030</o:Words>
  <o:Characters>5873</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>48</o:Lines>
  <o:Paragraphs>11</o:Paragraphs>
  <o:CharactersWithSpaces>7212</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
  <w:DrawingGridHorizontalSpacing>6 pt</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-font-kerning:16.0pt;}
h3
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:13.0pt;
	font-family:Arial;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 89.85pt 72.0pt 89.85pt;
	mso-header-margin:35.45pt;
	mso-footer-margin:35.45pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1030"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=blue style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:113.25pt;
 height:36.75pt'>
 <v:imagedata src="./Page2_files/image001.jpg" o:title="InterPro_logo"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=151 height=49
src="./Page2_files/image001.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:navy'>Ubiquitin<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='color:navy'>Ubiquitin-mediated Protein Degradation<o:p></o:p></span></h1>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span></p>

<table border=0 cellspacing=0 cellpadding=0 bgcolor="#e6e6e6" style='background:
 #E6E6E6;border-collapse:collapse;mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr>
  <td width=569 valign=top style='width:426.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoNormal align=center style='text-align:center'><!--[if gte vml 1]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:490.5pt;height:283.5pt'>
   <v:imagedata src="./Page2_files/image002.jpg" o:title="UB-26S_proteasome_2_cropped2"/>
  </v:shape><![endif]--><![if !vml]><img border=0 width=654 height=378
  src="./Page2_files/image003.jpg" v:shapes="_x0000_i1026"><![endif]></p>
  <p class=MsoNormal align=center style='text-align:center'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  </td>
 </tr>
 <tr>
  <td width=569 valign=top style='width:426.4pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal>Overview of the ubiquitin-mediated protein degradation
  pathway.</p>
  <p class=MsoNormal><span style='font-size:10.0pt;mso-bidi-font-size:12.0pt'>Reprinted
  from European Journal of Cancer 40, A.M. Burger and A.K. Seth, <i>The
  ubiquitin-mediated protein degradation pathway in cancer: therapeutic
  implications</i>, PP.2217-2229, 2004, <a
  href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15454246"
  title="AM Burger, AK Seth (2004) Eur J Cancer 40, pp.2217-2229, The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implic ">PMID:
  15454246</a><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>The
addition of a chain of multiple copies of ubiquitin (UB) targets a protein for
destruction by the intracellular protease known as the 26S proteasome, a large
complex that breaks down proteins to their constituent amino acids for
reuse.<span style="mso-spacerun: yes">  </span>The proteins targeted by this
system are short-lived proteins, many of which are regulatory proteins, whose
actions are controlled in part by rapid synthesis and degradation, much like an
on/off switch; as such, the UB system itself is an important regulatory tool
that controls the concentration of key signalling proteins.<span
style="mso-spacerun: yes">  </span>For example, many cell cycle regulatory
proteins, such as cyclin, are controlled by UB-mediated proteolysis to allow a
rapid transition between cell cycle stages, and to drive the direction of the
cell cycle by preventing regression to an earlier stage.<span
style="mso-spacerun: yes">  </span>The selective UB-mediated degradation of
proteins is also involved in the stress response, antigen processing, signal
transduction, transcriptional regulation, DNA repair and apoptosis.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>In addition,
the 26S proteasome targets misfolded, damaged or mutant proteins with abnormal
conformations that could be harmful to the cell.<span style="mso-spacerun:
yes">  </span>UB-dependent proteolysis provides the cell with a proofreading
capacity for nascent polypeptide chains, whereby faulty polypeptides are
targeted for destruction. <span style="mso-spacerun: yes"> </span>Sequences that
signal UB-mediated destruction can be buried in a hydrophobic core, which only
becomes exposed after misfolding, providing a convenient way to distinguish misfolded
proteins from functional ones - however, the presence of chaperones protects a
polypeptide from degradation from the time it is synthesised until it is fully
folded.<span style="mso-spacerun: yes">  </span>Damaged proteins are also
targeted.<span style="mso-spacerun: yes">  </span>For example, hepatic
cytochromes P450 are haemoproteins engaged in the oxidation of endo- and
xenobiotics, during which they can become damaged by reactive intermediates; these
damaged liver enzymes are rapidly removed by the UB-dependent proteolytic
system.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>It is
important for a cell to be able to select specific proteins for degradation so
as to avoid degrading proteins vital to the functioning of the cell, as well as
to precisely control the delicate balance that exists between the proteins in a
regulatory system, and to cope with the cell’s ever-changing protein
requirements.<span style="mso-spacerun: yes">  </span>The ubiquitin-mediated
pathway achieves a high level of specificity, selecting only UB-tagged proteins
to be destroyed.<span style="mso-spacerun: yes">  </span>In addition, there
exists a class of enzymes that function to remove UB from substrate proteins,
thereby rescuing them from destruction by preventing indiscriminate degradation.<span
style="mso-spacerun: yes">  </span>Thus, for a protein to be degraded, it must
not only have some type of UB-tagging signal, but also must escape the
de-ubiquitinylation enzymes.<span style="mso-spacerun: yes">  </span>The
attachment of UB to a target protein requires the action of three enzymes,
called E1 (UB-activating enzymes), E2 (UB-conjugating enzymes) and E3 (UB
ligases), which work sequentially in a cascade:</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Ubiquitin activation<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>E1
enzymes are responsible for activating UB, the first step in
ubiquitinylation.<span style="mso-spacerun: yes">  </span>The E1 enzyme
hydrolyses ATP and adenylates the C-terminus of UB, and then forms a thioester
bond between the C-terminus of UB and the active site cysteine of E1.<span
style="mso-spacerun: yes">  </span>To be fully active, E1 must non-covalently
bind to and adenylate a second UB molecule.<span style="mso-spacerun: yes"> 
</span>The E1 enzyme can then transfer the thioester-linked UB to the
UB-conjugating enzyme, E2, in an ATP-dependent reaction.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Ubiquitin conjugation<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>UB
is linked by another thioester bond to the active site cysteine of the E2
enzyme.<span style="mso-spacerun: yes">  </span>There are several different E2
enzymes (&gt;30 in humans), which are broadly grouped into four classes, all of
which have a core catalytic domain, and some of which have short C- or
N-terminal extensions that are involved in E2 localisation or in
protein-protein interactions.<span style="mso-spacerun: yes">  </span>The
different E2 enzymes are able to interact with overlapping sets of E3 ligases.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Ubiquitin ligation<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>With
the help of a third enzyme, E3 ligase, UB is transferred from the E2 enzyme to
a lysine residue on a substrate protein, resulting in an isopeptide bond
between the substrate lysine and the C-terminus of UB.<span
style="mso-spacerun: yes">  </span>UB ligation provides the key steps of substrate
selection and UB transfer to the protein target, with the E3 ligases being
responsible for substrate specificity and regulation of the ubiquitinylation
process.<span style="mso-spacerun: yes">  </span>Hundreds of putative E3
ligases have been identified, which bind to specific substrate sequences, or
“degrons” (as they are targets for degradation), permitting the substrate
specificity associated with this enzyme.<span style="mso-spacerun: yes"> 
</span>There are at least four classes of E3 ligases: HECT-type (<a
href="http://www.ebi.ac.uk/interpro/DisplayIproEntry?ac=IPR000569"
title="InterPro entry for HECT domain">IPR000569</a>), RING-type (<a
href="http://www.ebi.ac.uk/interpro/DisplayIproEntry?ac=IPR001841"
title="InterPro entry for RING domain">IPR001841</a>), PHD-type, and U-box
containing (<a
href="http://www.ebi.ac.uk/interpro/DisplayIproEntry?ac=IPR003613"
title="InterPro entry for U-box domain">IPR003613</a>).<span
style="mso-spacerun: yes">  </span>The E3 ligases are the only one of the 3
enzymes that is subjected to regulation, however balance in the UB system is
also achieved through a set of de-ubiquitinylating isopeptidases that cleave UB
off substrates.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Ubiquitin elongation<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'>Additional UB molecules can be
linked to the first one to form a poly-UB chain, which occurs through a
particular type of E3 ligase sometimes referred to as a UB-elongation enzyme,
or E4.<span style="mso-spacerun: yes">  </span>There are seven lysine residues in
UB that can be used to link UB molecules together, resulting in diverse
structures.<span style="mso-spacerun: yes">  </span>Poly-UB chains linked at
different positions alters the destiny of the target protein to which it is
added:<span style="mso-spacerun: yes">  </span>Lys(11)-, Lys(29)- and
Lys(48)-linked poly-UB chains target the protein to the proteasome for
degradation, while Lys(6)- or Lys(63)-linked poly-UB chains (as well as
mono-ubiquitinylation) signal reversible modifications in protein activity,
location or trafficking.<span style="mso-spacerun: yes">  </span>The length of
the UB chain appears to be important as well, such as with Lys(48) poly-UB
chains where its length influences its affinity for proteasomes.<span
style="mso-spacerun: yes">  </span>Therefore, E3 ligases provide the exquisite
specificity in regards to which proteins should be targeted with UB, how many
UB molecules are added to the target, and at what positions the poly-UB
molecules are linked, thereby determining the future of the protein and the
precise role it will play.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-indent:36.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Proteasome<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>The
26S proteasome is a large (&gt;60 subunits) complex with a 20S barrel-shaped
proteolytic core consisting of alternating <span style='font-family:Symbol'>a</span>
and <span style='font-family:Symbol'>b</span> subunits, and two 19S regulatory
“caps” at either end (see diagram above).<span style="mso-spacerun: yes"> 
</span>The 19S caps recognise, de-ubiquitinylate and unfold the target protein
before it is pulled through the hollow core of the 20S catalytic centre, where
it is dissembled into reusable amino acid components.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Disease<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Inappropriate
UB-mediated protein degradation has been implicated in a number of pathological
conditions, especially neurodegenerative disorders that involve protein
aggregation and inclusion body formation, such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease and ALS, where protein misfolding may
play a role.<span style="mso-spacerun: yes">  </span>Several Parkinson’s
disease-causing mutations have been identified in genes encoding for
UB-mediated degradation pathway proteins, such as the PARK2-encoded Parkin
protein that causes autosomal recessive juvenile parkinsonism (AR-JP), and
which appears to function as an E3 ligase.<span style="mso-spacerun: yes"> 
</span>This degradation pathway is also implicated in certain forms of cancer
as well.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=center style='text-align:center'>Next:<span style="mso-spacerun:
yes">  </span><a href="Page3.htm">The Many Roles of Ubiquitin</a></h1>

<h1 align=center style='text-align:center'>Previous: <a href="Page1.htm">Ubiquitin,
Prize Material</a></h1>

</div>

</body>

</html>
